MetaCap

AbbVie (ABBV) vs Abbott Laboratories (ABT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbbVie (ABBV) has outperformed Abbott Laboratories (ABT) over the past year, gaining 21.1% versus a loss of 19.6%. Over five years, ABBV leads with a +145.6% price change compared with -18.2% for ABT. AbbVie is the larger company by market cap ($505.89 billion vs $178.39 billion), about 2.8 times the size.

On valuation, Abbott Laboratories trades at a lower forward P/E (17.3x vs 17.6x for AbbVie). Abbott Laboratories offers the higher dividend yield (2.45% vs 2.42%). Abbott Laboratories converts more of its revenue into profit, with a net margin of 14.7% versus 6.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABBV+21.13%ABT-19.60%
+28%-5%-39%
Nov 21, 20251 yearNov 20, 2026
ABBV+146.21%ABT-18.80%
+163%+60%-43%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABBV versus ABT key metrics
MetricABBVABT
Share price$286.20$103.00
Market cap$505.89B$178.39B
1-day change+0.94%-0.84%
YTD return+25.26%-17.79%
1-year return+21.13%-19.60%
5-year return+145.64%-18.18%
P/E ratio (TTM)49.1838.43
Forward P/E17.6517.35
EPS (TTM)$5.82$2.68
Dividend yield2.42%2.45%
Annual dividend$6.92$2.52
Revenue (latest FY)$61.16B$44.33B
Revenue growth (YoY)+8.57%+5.67%
Net income (latest FY)$4.23B$6.52B
Gross margin70.24%56.42%
Operating margin24.65%18.17%
Net margin6.91%14.72%
52-week high$302.93$129.85
52-week low$190.75$81.97
Distance from 52-week high-5.52%-20.68%
Analyst consensusbuybuy
Avg. price target upside+9.76%+15.45%
Average volume4.84M8.89M
Shares outstanding1.77B1.73B
Employees57,000122,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AbbVie is about 2.8 times larger than Abbott Laboratories by market value ($505.89B vs $178.39B).
  • ABBV has outperformed ABT by 40.7 percentage points over the past year.
  • AbbVie trades at a higher earnings multiple (49.2x vs 38.4x trailing P/E).
  • Abbott Laboratories is more profitable, keeping 14.7 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.

About AbbVie

ABBV stock →

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees

About Abbott Laboratories

ABT stock →

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees

ABBV vs ABT FAQ

Which is bigger, AbbVie or Abbott Laboratories?

AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $178.39B for Abbott Laboratories (ABT).

Which stock has performed better over the past year, ABBV or ABT?

ABBV returned +21.13% over the past 12 months, compared with -19.60% for ABT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABBV or ABT?

ABT has the lower trailing P/E at 38.4, versus 49.2 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AbbVie or Abbott Laboratories?

Abbott Laboratories has the higher yield at 2.45%, compared with 2.42% for AbbVie.

Are AbbVie and Abbott Laboratories in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons